Konski and Brinckerhoff Quoted on Myriad Patent Eligibility

15 October 2014 Managing IP News

Managing IP

Foley Partners Antoinette Konski and Courtenay Brinckerhoff were quoted in a Managing IP article, “Federal Circuit Arguments in Myriad May Worry Biotech Industry,” on October 15, 2014. The story discussed the current patent case involving Myriad Genetics’ BRCA1/BRCA2 diagnostic tests.

Brinckerhoff was quoted saying, “The easiest decision for the Federal Circuit to reach would be to affirm based on the ‘substantial question’ standard without deciding patent eligibility on the merits. As Myriad’s counsel suggested, such a decision would leave the biotech industry ‘at sea’ until the case makes it back to the Federal Circuit again.”

Konski addressed the impact of the ruling and said, “This case is important because during oral argument what I captured is the Federal Circuit appears to be trying to have a test or an analytical framework that could be applied to inventions across a spectrum of technologies. That’s a more general importance. More specifically it really goes to how is one going to apply the decision holding in Myriad, what did the Supreme Court intend, and what remains as patent eligible after that decision.”

Related Services

Insights

A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Cloud security inadequate for Cyber threats, are you surprised?
19 July 2019
Internet, IT & e-Discovery Blog
Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ